Direct-to-consumer (DTC) medical testing is poised to reshape healthcare by empowering individuals with personal health information and driving scientific breakthroughs. However, experts caution that these tests can also lead to harm, often not from the tests themselves, but from the actions taken to manage the information they produce.
Dr. Matthew S. Davenport writes that the core issue arises when individuals act on information of unknown significance generated by these tests. He notes that humans are not always rational decision-makers, and the instinct to act upon findings can lead to unnecessary interventions. The potential for harm exists when seemingly innocuous tests yield results that prompt further action, even when such action may not be medically indicated.
As DTC testing becomes more prevalent, consumers are urged to scrutinize company claims. It is crucial to understand whether a test is positioned as a curiosity, an entertainment product, a research tool, or a pathway to clinical care. The lines between these categories are frequently blurred by companies, making informed purchasing decisions challenging.
The need for robust scientific validation, transparent disclosure, and regulatory oversight intensifies as a test moves from a purely informational or diagnostic purpose toward clinical application. If a test has only demonstrated its ability to provide information or diagnose a condition, or if its health benefits have only been proven in patients with specific risk factors that do not apply to the individual, a healthy skepticism is warranted. As the saying goes, buyers should beware.